Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)

NCT00450385 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

57

Enrollment

OTHER

Sponsor class

Stopped Investigator Decision due to insufficient accrual.

Conditions

Lymphoma

Interventions

DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Prednisone
DRUG: Vincristine

Sponsor

University of Miami